Uncomplicated Plasmodium Falciparum Malaria
Conditions
Keywords
Artemether, Lumefantrine, Amodiaquine, Artesunate, Triple Artemisinin-based Combination Therapy (TACT)
Brief summary
The goal of this open-label randomised, controlled, non-inferiority trial is to assess and compare the efficacy, tolerability and safety of a fixed dose TACT artemether-lumefantrine-amodiaquine (ALAQ) to the ACTs artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ) (with single low-dose primaquine in some sites) for the treatment of uncomplicated Plasmodium falciparum malaria in patient. The main question it aims to answer is whether ALAQ, a fixed dose TACT, is as efficacious, safe and tolerable in comparison with AL and ASAQ. Participants will be enrolled, admitted and randomised to receive the study drug (ALAQ, AL or ASAQ). Patients will receive directly observed treatments and will be followed up at least once daily for the first 3 days after enrolment followed by weekly visits from D7 up to D42. Patients will be asked to report to the clinics between scheduled visits in case of any illness or other symptoms or complaints.
Detailed description
Study participants with an uncomplicated P. falciparum monoinfection complying with all the inclusion criteria and without any of the exclusion criteria will be enrolled and randomised to three arms TACT (ALAQ), ACT1 (AL), ACT2 (ASAQ) at the sites in Africa and two arms TACT (ALAQ) and ACT (AL) at the site in Asia. Competitive recruitment with overall trial sample size 1,680 subjects (840 ALAQ, 420 AL, 420 ASAQ, i.e. a 2:1:1 ratio overall). In lower transmission settings (Annual Parasite Incidence \<50 per 1000 population per year) the treatment will include a single 0.25 mg/kg gametocytocidal dose of primaquine as recommended by the World Health Organization (WHO) for patients ≥10 kg. Primaquine may be given if local treatment policy includes it. Participants will be admitted for three days to an in-patient unit for directly observed treatment and to perform all the required study procedures from D0H0 (time of first dose intake) to D3 (H72). They will be followed up weekly starting D7 up to D42. Microscopy to detect and quantify malaria parasitaemia will be performed daily (more frequently in participants with parasite density of \>5000/µL at screening) during hospitalization and at all weekly and unscheduled visits. In participants with parasite densities \>5000/µL at screening, parasite clearance rates will be assessed by repeated assessments of the parasite counts after the start of the antimalarial treatments. A capillary blood sample will be taken at each of the time-points for these parasite counts. A physical examination and measurements of vital signs along with a symptom questionnaire will be performed and recorded through a standardized method at baseline, daily during admission and weekly during follow up through D42 and at all unscheduled visits. Safety assessments will be performed by measuring markers of renal and hepatic toxicity, haemoglobin, platelet counts, absolute and differential white blood cell counts and electrocardiographs (ECGs). ECGs will be performed during hospitalization (H0, H4, and 4 hours after the last dose) and day 42 of follow up to assess and compare the effect of the TACT and ACTs on QT or corrected QT (QTc) intervals. Pharmacokinetic measurements will be linked to measures of efficacy and toxicity. To reduce the burden of blood draws, especially in children, a population pharmacokinetic approach requiring sparse blood sampling will be followed in a subset of participants. Blood samples for parasite genotyping as well as genomic and transcriptomic studies will be collected at baseline and also on the day of a recurrent infection. In selected study sites, P. falciparum parasites will be cryopreserved for in vitro antimalarial drug sensitivity testing. Where possible, ex vivo or in vitro assessments of parasite susceptibility to artemisinins and partner drugs will be assessed. The in vivo and ex vivo data on artemisinin and partner drug sensitivity will potentially be used to identify new genetic or transcriptomic markers/patterns of artemisinin or partner drug resistance. The trial has been funded by Global Health Innovative Technology Fund.
Interventions
DRUGArtemether-Lumefantrine-Amodiaquine (ALAQ)
A new fixed-dose combination containing artemether, lumefantrine and amodiaquine (ALAQ) will be used in the trial. Each paediatric (dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine, 40 mg amodiaquine. Two formulations of (non-dispersible/hard) tablets, containing 50 mg or 60 mg artemether, 300 or 360 mg lumefantrine and 100 or 120 mg amodiaquine, will be used for adolescents or adults. The treatments will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine, 22.5-45 mg/kg of amodiaquine).
A fixed-dose combination of AL will be used in the trial. Each paediatric (dispersible or non-dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine and adult (non-dispersible) tablets will contain 80 mg artemether, 480 mg lumefantrine. Treatment doses will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO.
ASAQ will also be administered as a fixed dose combination. The tablets will contain 25 mg of artesunate and 67.5 mg of amodiaquine in the paediatric formulation and 100 mg artesunate, 270 mg amodiaquine in the adult formulation. The dosing will be administered once a day for 3 days at H0, H24 and H48 according to the schedule currently recommended by the WHO.
Sponsors
University of Oxford
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female, aged ≥6 months (no upper limit unless one is required by local regulations) and bodyweight ≥5 kg * Ability to take oral medication * Fever defined as ≥38°C tympanic temperature or a history of fever within the last 24 hours * Acute uncomplicated P. falciparum monoinfection * Asexual P. falciparum parasitaemia: 1,000/µL to 250,000/µL determined on a peripheral blood film * Written informed consent by the participant, or by the parent/guardian in case of children lower than the age of consent, and assent if required (per local regulations) * Willingness and ability of the participants or parents/guardians to comply with the study protocol for the duration of the study
Exclusion criteria
* Signs of severe malaria (adapted from WHO criteria) * Patients not fulfilling criteria for severe malaria but with other indication(s) for parenteral antimalarial treatment at the discretion of the treating physician * Haemoglobin \<7 g/dL at screening * Participants who have received artemisinin or a derivative within the previous 7 days OR lumefantrine or amodiaquine within the previous 14 days * In applicable countries: use of seasonal malaria chemoprophylaxis (SMC) within the last 30 days * Acute illness other than malaria requiring systemic treatment * Severe acute malnutrition * Known HIV, tuberculosis, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or other severe infection * For women of child-bearing age: pregnant, trying to get pregnant or lactating * History of allergy or known contraindication to any of the study drugs, including neuropsychiatric disorders and epilepsy * Previous splenectomy * Participation in the previous 3 months and/or ongoing follow-up for an interventional study (including FD-TACT)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 28-day efficacy | 28 days | 28-day efficacy defined as the proportion of patients with Polymerase Chain Reaction (PCR)-corrected adequate clinical and parasitological response (ACPR) at Day 28, i.e., absence up to Day 28 of P. falciparum parasitaemia (detected by microscopy) with parasites genetically identical to those detected at baseline (as determined by PCR product length polymorphisms) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 42-day PCR-uncorrected efficacy | 42 days | 42-day PCR-uncorrected efficacy defined as the proportion of patients with absence up to Day 42 of P. falciparum parasitaemia |
| Parasite clearance half-life | 3 days | Assessed by microscopy as primary parameter to determine parasite clearance half-life |
| Proportion of participants with microscopically detectable P. falciparum parasitaemia at Day 3 | 3 days | — |
| Fever clearance time | 42 days | Fever clearance time (i.e., the time taken for the tympanic temperature to fall below 37.5°C in participants who were febrile at inclusion) |
| Proportion of participants with gametocytaemia | 42 days | Proportion of participants with gametocytaemia during and after treatment stratified by presence of gametocytes at enrolment |
| Incidence of adverse events (AEs) | 42 days | Incidence of AEs within the first 42 days including markers of hepatic, renal or bone marrow toxicity |
| Incidence of serious adverse events (SAEs) | 42 days | Incidence of SAEs within the first 42 days including markers of hepatic, renal or bone marrow toxicity |
| Number of cardiotoxicity events | 42 days | Cardiotoxicity in particular QT or QTc-interval above 500 ms at timepoint H4, H52 or H64, D42 |
| Proportion of participants requiring retreatment due to vomiting | 1 hour after administration of each dose of the treatment | Proportion of participants requiring retreatment due to vomiting within 1 hour after administration of the study drugs |
| Proportion of participants who report completing a full course of observed TACT | 3 days | Proportion of participants who report completing a full course of observed TACT without withdrawal of consent or exclusion from study because of drug related serious adverse event |
| Proportion of participants who report completing a full course of observed ACT | 2 or 3 days depending on the treatment | Proportion of participants who report completing a full course of observed ACT without withdrawal of consent or exclusion from study because of drug related serious adverse event |
| Peak plasma concentration | 42 days | Peak plasma concentration (Cmax) of artemisinin-derivatives and partner drugs in ACT and TACT treated participants in correlation with pharmacodynamics measures of drug efficacy |
| Area under curve | 42 days | Area under the plasma concentration versus time curve (AUC) of artemisinin-derivatives and partner drugs in ACT and TACT treated participants in correlation with pharmacodynamic measures of drug efficacy |
| Pharmacokinetic interactions - peak plasma concentration | 42 days | Comparison of peak plasma concentration (Cmax) of artemisinin-derivatives and partner drugs in ACT and TACT treated participants in correlation with pharmacodynamics measures of drug efficacy |
| Pharmacokinetic interactions - area under curve | 42 days | Comparison of area under the plasma concentration versus time curve (AUC) of artemisinin-derivatives and partner drugs in ACT and TACT treated participants in correlation with pharmacodynamic measures of drug efficacy |
| Plasma levels of partner drugs | 7 days | Plasma levels of partner drugs in correlation with treatment efficacy and treatment arm on Day 7 |
| 28-day PCR uncorrected efficacy | 28 days | 28-day PCR uncorrected efficacy defined as the proportion of patients with absence up to Day 28 of P. falciparum parasitaemia |
| 42-day efficacy | 42 days | 42-day efficacy defined as the proportion of patients with PCR-corrected adequate clinical and parasitological response (ACPR) at Day 42, i.e., absence up to Day 42 of P. falciparum parasitaemia (detected by microscopy) with parasites genetically identical to those detected at baseline (as determined by PCR product length polymorphisms) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Comparison of 28-day PCR-corrected efficacy of ALAQ vs AL | 28 days | Comparison of 28-day PCR-corrected ACPR (as defined in outcome measure 1) of ALAQ vs AL in infections with parasites carrying known and/or candidate markers of antimalarial drug resistance (mutations in pfkelch13, pfcrt, pfmdr1 and/or other markers, including those identified over the course of the study) |
| Comparison of 28-day PCR-uncorrected efficacy of ALAQ vs AL | 28 days | Comparison of 28-day PCR-uncorrected efficacy (as defined in outcome measure 2) of ALAQ vs AL in infections with parasites carrying known and/or candidate markers of antimalarial drug resistance (mutations in pfkelch13, pfcrt, pfmdr1 and/or other markers, including those identified over the course of the study) |
| Comparison of 42-day PCR-corrected efficacy of ALAQ vs AL | 42 days | Comparison of 42-day PCR-corrected ACPR (as defined in outcome measure 3) of ALAQ vs AL in infections with parasites carrying known and/or candidate markers of antimalarial drug resistance (mutations in pfkelch13, pfcrt, pfmdr1 and/or other markers, including those identified over the course of the study) |
| Comparison of 42-day PCR-uncorrected efficacy of ALAQ vs AL | 42 days | Comparison of 42-day PCR-uncorrected efficacy (as defined in outcome measure 4) of ALAQ vs AL in infections with parasites carrying known and/or candidate markers of antimalarial drug resistance (mutations in pfkelch13, pfcrt, pfmdr1 and/or other markers, including those identified over the course of the study) |
| Comparison of 28-day PCR-corrected efficacy of ALAQ vs ASAQ | 28 days | Comparison of 28-day PCR-corrected ACPR (as defined in outcome measure 1) of ALAQ vs ASAQ in infections with parasites carrying known and/or candidate markers of antimalarial drug resistance (mutations in pfkelch13, pfcrt, pfmdr1 and/or other markers, including those identified over the course of the study) |
| Comparison of 28-day PCR-uncorrected efficacy of ALAQ vs ASAQ | 28 days | Comparison of 28-day PCR-uncorrected efficacy (as defined in outcome measure 2) of ALAQ vs ASAQ in infections with parasites carrying known and/or candidate markers of antimalarial drug resistance (mutations in pfkelch13, pfcrt, pfmdr1 and/or other markers, including those identified over the course of the study) |
| Comparison of 42-day PCR-corrected efficacy of ALAQ vs ASAQ | 42 days | Comparison of 42-day PCR-corrected ACPR (as defined in outcome measure 3) of ALAQ vs ASAQ in infections with parasites carrying known and/or candidate markers of antimalarial drug resistance (mutations in pfkelch13, pfcrt, pfmdr1 and/or other markers, including those identified over the course of the study) |
| Comparison of 42-day PCR-uncorrected efficacy of ALAQ vs ASAQ | 42 days | Comparison of 42-day PCR-uncorrected efficacy (as defined in outcome measure 4) of ALAQ vs ASAQ in infections with parasites carrying known and/or candidate markers of antimalarial drug resistance (mutations in pfkelch13, pfcrt, pfmdr1 and/or other markers, including those identified over the course of the study) |
| Proportions of recurrent infections with mutations | 42 days | Proportions of recurrent infections with parasites carrying mutations known to be associated with recrudescence |
| Proportions of specimens collected at baseline with parasites carrying mutations | Baseline | Proportions of specimens collected at baseline with parasites carrying mutations of known functional or operational significance (pfkelch13, pfcrt, pfmdr1, pfdhfr, pfdhps, pfplasmepsin2, and/or other parasite genetic markers associated with resistance or identified over the course of the study) |
| Change in haemoglobin concentration stratified for Glucose-6-Phosphate Dehydrogenase (G6PD) status/genotype | 28 days | Change in haemoglobin concentration at day 3, 7, 28, stratified for G6PD status/genotype in participants receiving single low dose primaquine (SLD-PQ) vs those not receiving it |
| Comparison of transcriptomic patterns of drug sensitive and resistant parasites | 24 hours | Comparison of levels of RNA transcription before treatment and 6, 12 and 24 hours after start of treatment between parasites with or without known or putative markers of drug resistance |
| Levels of RNA transcription coding for male or female specific gametocytes | 14 days | Levels of RNA transcription coding for male or female specific gametocytes at admission up to day 14, stratified by the presence of gametocytes at enrolment |
| In vitro susceptibility of P. falciparum to artemisinins and partner drugs | 42 days | In vitro susceptibility, measured as % survival after drug exposure or as half-maximal inhibitory concentration (IC50), of P. falciparum to artemisinins and partner drugs according to study sites and genotype |
| Ex vivo susceptibility of P. falciparum to artemisinins and partner drugs | 42 days | Ex vivo susceptibility, measured as % survival after drug exposure or as IC50, of P. falciparum to artemisinins and partner drugs according to study sites and genotype |
Countries
Rwanda
Contacts
Primary ContactMehul Dhorda, Ph.D
Backup ContactArjen Dondorp, Prof.
Outcome results
None listed